Quince Therapeutics (QNCX) Enterprise Value (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Enterprise Value of -$3.0 million for Q1 2026, up 89.76% year-over-year from -$1.6 million in Q1 2025, and up 81.51% quarter-over-quarter from -$16.3 million in Q4 2025.
Quince Therapeutics (QNCX) Enterprise Value (2018 - 2026) Analysis & Trends
Quince Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$3.0 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 89.76% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at -$3.0 million (up 89.76% YoY), while the FY2025 annual figure was -$16.3 million, up 55.92% from the prior year.
- Enterprise Value for Q1 2026 stood at -$3.0 million, up from -$16.3 million in the prior quarter.
- The five-year high for Enterprise Value was -$3.0 million in Q1 2026, with the low at -$112.2 million in Q1 2024.
- The 5-year median for Enterprise Value is -$75.1 million (2023), against an average of -$63.1 million.
- The sharpest annual moves came in 2024 and 2026: Enterprise Value dropped 24.43% in 2024, then jumped 89.76% in 2026.
- Quince Therapeutics' Enterprise Value stood at -$90.2 million in 2022, then grew by 16.77% to -$75.1 million in 2023, then soared by 50.6% to -$37.1 million in 2024, then jumped by 55.92% to -$16.3 million in 2025, then jumped by 81.51% to -$3.0 million in 2026.
- Business Quant data shows QNCX's Enterprise Value at -$3.0 million in Q1 2026, -$16.3 million in Q4 2025, and -$26.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 27.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.02 Mn |
| Dec 31, 2025 | -16.35 Mn |
| Sep 30, 2025 | -26.29 Mn |
| Jun 30, 2025 | -34.71 Mn |
| Mar 31, 2025 | -29.51 Mn |
| Dec 31, 2024 | -37.08 Mn |
| Sep 30, 2024 | -47.85 Mn |
| Jun 30, 2024 | -59.45 Mn |
| Mar 31, 2024 | -112.24 Mn |
| Dec 31, 2023 | -75.06 Mn |
| Sep 30, 2023 | -83.23 Mn |
| Jun 30, 2023 | -87.57 Mn |
| Mar 31, 2023 | -90.20 Mn |
| Dec 31, 2022 | -90.18 Mn |
| Sep 30, 2022 | -94.34 Mn |
| Jun 30, 2022 | -94.66 Mn |
| Mar 31, 2022 | -91.52 Mn |
| Dec 31, 2021 | -106.80 Mn |
| Sep 30, 2021 | -114.41 Mn |
| Jun 30, 2021 | -129.95 Mn |